Last reviewed · How we verify
Neo-T
At a glance
| Generic name | Neo-T |
|---|---|
| Also known as | Neoantigen targeting T cells Suspension for Intravenous Infusion |
| Sponsor | BGI, China |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (PHASE2)
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG (PHASE1)
- Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (PHASE2)
- Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells (PHASE1)
- Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer (PHASE2)
- Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (PHASE2)
- The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT) (PHASE2)
- Basket Study for Oligo-metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neo-T CI brief — competitive landscape report
- Neo-T updates RSS · CI watch RSS
- BGI, China portfolio CI